Standard Alzheimer's treatment uses FDA-approved care, while a clinical trial tests an intervention under a research protocol with greater uncertainty. Trials may cover research costs, but routine care may still be billed; both choices require weighing risks, burdens, and consent. The choice is not always either/or. Medicare coverage for certain anti-amyloid treatments requires registry data collection, but participation in that registry is not random assignment to a clinical trial.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Official resources:
- ClinicalTrials.gov Alzheimer's disease trial registry — Use this record to verify the study status and eligibility details.
- Check eligibility on ClinicalTrials.gov’s official study page — Use this page to check the study’s participation requirements.
Table of Contents
- What counts as standard treatment?
- How much benefit—and what risk?
- Who pays for what?
- What valid consent should include
- How to judge whether a trial fits
What counts as standard treatment?
Standard care includes symptom medicines such as donepezil, galantamine, and rivastigmine. It also includes the anti-amyloid immunotherapies lecanemab and donanemab for early Alzheimer's disease, according to the National Institute on Aging's treatment guide. None of these treatments cures Alzheimer's. Lecanemab and donanemab aim to slow decline rather than restore lost memory or function.
Treatment begins only in the early stages studied: mild cognitive impairment due to Alzheimer's or mild Alzheimer's dementia, with amyloid disease confirmed. Medicare covers eligible FDA-approved anti-amyloid antibodies through approved registries or studies. Clinicians submit baseline and six-month data for up to 24 months. This evidence collection differs from a randomized trial, where a protocol may assign participants to an investigational treatment, placebo, or comparison group.
How much benefit—and what risk?
The strongest evidence shows modest slowing of decline, not improvement. In CLARITY-AD, 1,795 participants receiving lecanemab had 27% less decline on an 18-month clinical scale than those receiving placebo—a 0.45-point difference, according to the FDA's revised lecanemab label. In TRAILBLAZER-ALZ 2, donanemab produced a 3.25-point difference at 76 weeks in participants with low or medium tau levels. That represented 35.1% relative slowing, but both groups continued to decline.
Anti-amyloid drugs can cause amyloid-related imaging abnormalities, or ARIA. These abnormalities involve brain swelling, bleeding, or both and require MRI monitoring. Lecanemab carries greater ARIA risk for people with two copies of the APOE ε4 gene, while anticoagulant use raises additional concern about brain bleeding. A trial may add unknown risks because researchers are still establishing safety or effectiveness. Its protocol may also require visits, testing, or treatment schedules beyond ordinary clinical care.
Who pays for what?
Approved treatment is billed as clinical care, subject to the patient's insurance coverage and cost sharing. For anti-amyloid treatment, ask for an estimate that separates the medicine from infusions, required MRI scans, clinician visits, and other monitoring. Many trials pay for the experimental intervention and research-only visits.
They do not necessarily cover routine medical care, which may be billed to the participant or insurance. Before enrolling, obtain written answers to these questions: Do not assume that "no-cost study drug" means cost-free participation. Time commitments and unpaid expenses should be considered alongside medical bills.
- Which treatments, scans, and visits does the study pay for?
- What will insurance be asked to cover?
- Could any procedure be denied as experimental?
- Are travel, parking, lodging, or caregiver expenses reimbursed?
- Who pays for care if the study intervention causes harm?
What valid consent should include
Informed consent is the process of learning what participation involves before agreeing. It should explain eligibility, procedures, time commitments, known risks and possible benefits, payment, and potential participant costs, as outlined by ClinicalTrials.gov. Consent is not a promise to finish the study.
A participant may withdraw at any time. Before signing, ask the research team to explain what happens after withdrawal, including follow-up requests and any remaining clinical-care costs. A family should be able to answer several practical questions in plain language: Take time to review the form and compare it with the spoken explanation. Unclear answers about assignment, risk, payment, or withdrawal deserve clarification before consent.
- Is the treatment approved, investigational, or a placebo?
- How is treatment assigned?
- What benefit is realistic, and what remains unknown?
- Which symptoms require an urgent call?
- How often are visits, infusions, tests, or MRI scans required?
How to judge whether a trial fits
Eligibility does not prove that a trial is the best treatment choice. Alzheimer's studies may enroll people with diagnosed disease, biomarkers or elevated risk, caregivers, or cognitively healthy volunteers. Drug trials commonly require a study partner.
Start by identifying the person's diagnosis and stage, whether amyloid has been confirmed, and whether approved treatment is available. Then compare the expected benefit, ARIA risk, monitoring burden, costs, trial assignment, and the person's preferences. Ask the treating clinician and research team the same core questions, then compare their answers. If a study's purpose, alternatives, costs, or withdrawal process remains unclear, do not sign until the consent discussion resolves it.
